Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

by the Efficacy Safety Monitoring Board.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomized, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. Interest around TB-402, which is given as a single injection post surgery and has several weeks of activity, is due to its potential to overcome the major drawbacks, such as spontaneous bleeding and the need for extensive patient monitoring, associated with current anti-coagulant therapy.

ThromboGenics and its development partner BioInvent plan to engage in discussions with potential partners for TB-402.

During this period, additional data from the earlier successful Phase I studies were presented at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) on July 15, 2009 in Boston by Professor Peter Verhamme from KULeuven.

    TB-403 (RG7334) - Novel anti-cancer agent partnered with Roche

    - Partnership with Roche continues to run smoothly with TB-403
      Phase Ib enrolment completed recently

In June 2008, ThromboGenics and its co-development partner BioInvent signed a strategic alliance deal with Roche for its novel anti-cancer agent, TB-403 (anti-PIGF). The partnership continues to run smoothly and enrolment for the Phase Ib trial was completed in the second quarter of 2009. This Phase Ib trial is assessing TB-403's tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer.

The results from this trial are currently planned to be presented at a scientific conference later this year.

In January 2009, ThromboGenics and BioInvent received their first success fee from Roche based on the successful transfer and implementation of technology and process development for TB-403 production. ThromboGenics received EUR3 million (60%) of the overall EUR5 million
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  A simple blood ... Science Center to detect early Alzheimer,s disease is a ... Detailed standardized guidelines that are needed before ... been published in Alzheimer,s & Dementia . The ... an international working group that includes UNT Health Science ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 ... the beginning of a long-term relationship with Veterinary ... behalf of its members to provide access to ... extremely pleased to count VGP as a dedicated ... arthritic dog patients nationwide. Concentrating and using stem ...
(Date:5/26/2015)... ANGELES , May 26, 2015 Mr. ... his family, thanks President Barack Obama and President ... during the time of loss of Dr. Rongxiang Xu ... humanitarian and a leader ahead of his time, Dr. Xu,s ... the community leave a legacy that will not be forgotten. ...
(Date:5/26/2015)... , May 26, 2015 Oramed ... a clinical-stage pharmaceutical company focused on the development of ... submitted the study protocol for the company,s Phase IIb ... U.S. Food and Drug Administration (FDA). The submission was ... application. The Phase IIb study of ORMD-0801 ...
Breaking Biology Technology:Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 2VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering 3Dr. Rongxiang Xu, Beyond A Legend 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... biobased industries could become a model for the rest of ... industry officials said at a leadership summit held Thursday at ... Wisconsin's forest and agricultural industry and its ties to the ... from the U.S. Department of Energy and the ...
... video-game developers gathered last week in Madison to explore ... education models, which speakers agreed early e-learning projects failed ... was sponsored by Games And Professional Practice ... Academic Distributed Learning (ADL) Co-Lab and a group ...
... suggest that scientists at UW-Madison or anywhere else in Wisconsin ... in the state has even announced plans to do so. ... process for cloning a human embryo for reproductive purposes is ... used in therapeutic cloning. The first step in both procedures ...
Cached Biology Technology:Wisconsins biobased industries could be world leader 2Wisconsins biobased industries could be world leader 3Gaming technologies alter classroom, textbook models 2Gaming technologies alter classroom, textbook models 3Gaming technologies alter classroom, textbook models 4Gaming technologies alter classroom, textbook models 5The Attack of the Clones: No, its not a summer movie 2The Attack of the Clones: No, its not a summer movie 3
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... Institute Associate Scientist Thomas Brutnell is helping lead a ... attempting to solve one of the "grand challenges" in ... plants will grow and develop based on their particular ... found or planted. Solving this problem requires new computer ...
... recently diverged populations of a southern California songbird produce ... isolation that accompanies the origin of new bird species. ... in the preen oils of Dark-eyed Juncos is described ... so much we don,t know about the role of ...
... Montreal, March 23, 2010 Age and gender play a ... a new study on 20-to-64-year-olds. Published in the journal ... Universit de Montral and the Montreal Heart Institute in collaboration ... McGill University. "Our findings suggest that women who are ...
Cached Biology News:BTI's Brutnell leads part of NSF Computational Plant Biology Research System 2BTI's Brutnell leads part of NSF Computational Plant Biology Research System 3Could smell play a role in the origin of new bird species? 2Could smell play a role in the origin of new bird species? 3Men and women respond differently to stress 2
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
... OA-Hy cis- 9-Octadecenoyl-N-hydroxylamide Oleoyl-N-hydroxylamide ... PACKAGED UNDER INERT GAS. A potent inhibitor ... manner (K i = 1.7 μM). ... in EtOH or DMSO. Unstable in solution, ...
... with an early protein. ... hours post-infection exhibiting an intranuclear ... intensity between 6-24 hours. ... coarsely granular staining. No ...
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Biology Products: